Telehealth Settles In as a Permanent Fixture of American Medicine
Once an emergency measure, virtual visits have become a routine option, especially for follow-ups and mental health care.
Telehealth, which surged out of necessity during the pandemic, has settled in as a permanent fixture of American medicine, with virtual visits now a routine option for many kinds of care rather than an emergency workaround.
The staying power surprised some skeptics who expected in-person visits to fully reclaim their dominance. Instead, patients and clinicians found that many encounters, from follow-ups to medication management, translate well to a screen.
Where it works best
Telehealth has proven especially valuable for mental health care, where the format suits ongoing talk therapy and has expanded access in areas with few providers. It also eases the burden for patients managing chronic conditions or facing transportation barriers.
It is not a universal substitute. Physical exams, procedures, and many diagnostic needs still require in-person care, and clinicians emphasize matching the visit type to the medical need rather than defaulting to virtual for everything.
Access and equity
The format's benefits depend on access to reliable internet and devices, a reminder that the digital divide shapes health care too. As telehealth cements its place, experts stress the importance of ensuring it broadens access rather than deepening existing gaps.
More in Health & Medicine
FDA Licenses the First Freeze-Dried Plasma Product in the U.S.
Regulators approved the country's first freeze-dried plasma, a shelf-stable blood product that could ease transfusion logistics in trauma care and emergency settings.
Health Officials Investigate a Multistate Cyclospora Outbreak Tied to Produce
Federal investigators are working to pin down the source of a cyclosporiasis outbreak reported across several states, a recurring summertime challenge linked to fresh produce.
FDA Advisory Panel Backs Compounding of Two Peptides, Drawing Expert Caution
A federal advisory committee recommended allowing two peptides to be compounded, but specialists warned the move could be misread as a sign the compounds have been fully vetted.